Portfolio Companies News
January 22, 2018PUBLICATION HIGHLIGHTS A NOVEL CERA...
Lund, Sweden, 08.00 CET, 22 January 2018 – BONESUPPORTTM, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique platform announces that a paper “Gelatin- hydroxyapat... read more
January 18, 2018Strongbridge Biopharma Receives Not...
Notice of Allowance to Lead to Second Method of Use Patent for RECORLEV ~DUBLIN, Ireland and TREVOSE, Pa., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of ther... read more
January 17, 2018Strongbridge Biopharma plc Announce...
~ MACRILEN is the First and Only FDA-Approved Oral Drug Indicated For the Diagnosis of Adult Growth Hormone Deficiency, a Rare Endocrine Disorder ~ ~ MACRILEN is Strongbridge’s Second Commercial Product; Expands the Company’s Rare Endocrine Disease Portfolio and Complements its Late-S... read more
January 10, 2018GenSight Biologics receives MHRA ap...
Paris, France, January 10, 2018, 7.30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced UK ... read more
January 9, 2018Pulmonx Submits Premarket Approval ...
Zephyr EBVs are the Only Minimally-Invasive, Removable Devices for Emphysema with Validated Diagnostic Tool to Select Patients Likely to Benefit from Treatment REDWOOD CITY, Calif. – January 9, 2018 – Pulmonx® Corp. today announced its filing of a Premarket Approval (PMA) application with ... read more
November 13, 2017Q3 2017 General Market Overview
Since the start in 1996, HealthCap funds have invested in 110 portfolio companies.
41 of the portfolio companies have been taken public on nine different markets.
24 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.